1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Philips NV
  6. News
  7. Summary
    PHIA   NL0000009538

PHILIPS NV

(PHIA)
  Report
Real-time Euronext Amsterdam  -  05/17 11:35:14 am EDT
23.91 EUR   +1.23%
10:29aRoyal Philips - New release of Philips EchoNavigator helps interventional teams treat structural heart disease with greater ease and efficiency
AQ
05/16Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022
GL
05/16Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

U.S. FDA labels Philips expanded ventilator recall as most serious

01/26/2022 | 02:53pm EDT

Jan 26 (Reuters) - The U.S. Food and Drug Administration (FDA) on Wednesday classified an expanded recall of certain ventilators by Philips late last year as Class 1, or the most serious type, saying they could lead to injuries or death.

The Dutch medical equipment company initiated the recall of 215 Trilogy Evo ventilators and 51 repair kits in the United States in December due to potential health risks from a type of foam used in the devices.

So far, there have been no reported injuries or deaths from the products, which were distributed in the United States and Korea, the FDA said.

"We have already reached the majority of affected customers and we will correct this issue via a repair on site in the coming months" a company spokesperson said in an emailed statement to Reuters.

This is the latest recall by Philips to be labeled Class 1 after it pulled back up to 4 million breathing-aid machines last year amid concerns that a polyurethane foam used in the devices could degrade and become toxic.

Earlier this month, the company raised that estimate by 1 million.

A Philips supplier had incorrectly used a type of polyurethane foam, which is intended to reduce sound and vibration, in one of the parts of the Trilogy Evo ventilators - an issue that was identified during lab testing, the regulator said on Wednesday.

The supplier used polyester-based polyurethane foam instead of a polyether-based one which is specified for these products and meets all applicable standards, Philips said in the email.

The polyester-based foam could break down and potentially enter the device's air pathway, leading to the user inhaling chemicals or other harmful materials, the FDA said.

($1 = 0.8880 euros) (Reporting by Amruta Khandekar; Editing by Devika Syamnath and Sriraj Kalluvila)


ę Reuters 2022
All news about PHILIPS NV
10:29aRoyal Philips - New release of Philips EchoNavigator helps interventional teams treat s..
AQ
05/16Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022
GL
05/16Philips showcases ultra-low contrast PCI solutions at EuroPCR 2022
AQ
05/16New release of Philips EchoNavigator helps interventional teams treat structural heart ..
GL
05/16Koninklijke Philips N.V. Announces the International Launch of EchoNavigator 4.0 at Eur..
CI
05/12PHILIPS NV : Ex-dividend day for final dividend (optional)
FA
05/10Shareholders Vote Down Philips' Executive Compensation Plan
MT
05/10Philips Annual General Meeting of Shareholders approves dividend and other proposals ma..
GL
05/10Royal Philips Approves Appointment of Mrs. Herna Verhagen and Mr. Sanjay Poonen as Memb..
CI
05/10Royal Philips Approves Dividend for the Year 2021
CI
More news
Analyst Recommendations on PHILIPS NV
More recommendations
Financials
Sales 2022 18 272 M 19 245 M 19 245 M
Net income 2022 806 M 849 M 849 M
Net Debt 2022 4 281 M 4 509 M 4 509 M
P/E ratio 2022 24,5x
Yield 2022 3,68%
Capitalization 20 785 M 21 624 M 21 893 M
EV / Sales 2022 1,37x
EV / Sales 2023 1,28x
Nbr of Employees 78 189
Free-Float 97,5%
Chart PHILIPS NV
Duration : Period :
Philips NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHILIPS NV
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 23,62 €
Average target price 32,18 €
Spread / Average Target 36,2%
EPS Revisions
Managers and Directors
Frans van Houten Chief Executive Officer
Abhijit Bhattacharya Chief Financial Officer & Executive Vice President
Feike Sijbesma Chairman-Supervisory Board
Jan Kimpen Chief Medical Officer
Sophie Bechu Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
PHILIPS NV-27.91%21 362
THERMO FISHER SCIENTIFIC-18.86%211 147
DANAHER CORPORATION-25.12%176 375
INTUITIVE SURGICAL, INC.-38.90%78 802
SIEMENS HEALTHINEERS AG-15.74%64 712
EDWARDS LIFESCIENCES CORPORATION-25.95%59 645